Beroni Group Ltd. Stocks

$ 0.01Last Updated 13.03.2026

Issuer Rating

3/7

Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 213144

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.01
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beroni Group Limited, together with its subsidiaries, develops and sells smoking control products, air purifiers, water filters, and health care products and supplements in China, Australia, the United States, and Japan. It operates through Nicobloc, Fogibloc Air Purifier, Olansi Water Filter, Health Supplements, Cosmetic products, and Viral Diagnostic Kits segments. The company's products include NicoBloc, a smoking cessation/harm reduction product; and Fogibloc, an air purifier system. It also offers cosmetic products, such as V show rejuvenation liquids, hyaluronic acid moisturizing silk masks, and avocado poly-peptide intensive treatment silk masks. In addition, the company provides SARS-CoV-2 IgG/IgM antibody detection kit, as well as sells CII-ArboViroPlex rRT-PCR assay, a diagnostic kit used to detect viruses such as Zika, Dengue, Chikungunya, and West Nile. Further, it engages in the research and development of new drugs and clinical trial; gene detection and diagnosis, as well as sale of cell therapies for cancer and anti-aging treatments; developing new anti-cancer drugs; detection and diagnosis of infectious diseases; and e-commerce platform for pharmaceutical and healthcare products. Additionally, the company sells stem cell cosmetic products. The company was founded in 2014 and is headquartered in Sydney, Australia.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks